UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017505
Receipt number R000020292
Scientific Title Brain Mapping by Integrated Neurotechnologies for Disease Studies: Human Brain Aging Imaging Study
Date of disclosure of the study information 2015/09/01
Last modified on 2019/05/14 10:11:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Brain Mapping by Integrated Neurotechnologies for Disease Studies: Human Brain Aging Imaging Study

Acronym

Brain/Minds Aging Imaging Study

Scientific Title

Brain Mapping by Integrated Neurotechnologies for Disease Studies: Human Brain Aging Imaging Study

Scientific Title:Acronym

Brain/Minds Aging Imaging Study

Region

Japan


Condition

Condition

Mild cognitive impairment, preclinical AD

Classification by specialty

Neurology Geriatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To apply functional MRI methodologies to the very early stage of Alzheimer disease, MRI imaging data including structural MRI, resting state functional MRI, diffusion tensor imaging and arterial spin labeling will be acquired in MCI or preclinical AD individuals.

Basic objectives2

Others

Basic objectives -Others

Compare the MRI data with amyloid PET images and cognitive data.

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Volumetric differences in the hippocampus and other areas in cognitive normal and MCI
Micro volumetric analysis of subregions of hippocampus and other medial temporal areas in cognitive normal and MCI
Differences in cerebral blood flow using ASL in cognitive normal and MCI
Differences in functional connectivity using rsfMRI in cognitive normal and MCI
Differences in DTI parameters in cognitive normal and MCI
Differences in brain volume in hippocampal and other areas in amyloid positive and negative individuals
Differences in volume of subregions of hippocampus and other medial temporal areas in amyloid positive and negative individuals
Differences in ASL and rsfMRI parameters in amyloid positive and negative individuals
Differences in DTI parameters in amyloid positive and negative individuals

Key secondary outcomes



Base

Study type


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Other

Interventions/Control_1

Brain Positron Imaging by intravenous administration of 11C-labeled amyloid PET diagnostic drug

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

60 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

Cognitive normal aged individual with CDR score 0 or MCI with CDR score 0.5 (memory box >= 0.5); amyloid PET positive cognitive normal is categorized as preclinical AD and those negative as normal aged.
A study partner is available
Age 60-90
MRI eligible
Other dementing illness is not diagnosed. No past history of intracranial diseases.

Key exclusion criteria

No past history of major depression or bipolar disorder, schizophrenia, alcoholism or drug addiction.
CT or MRI findings indicative of cerebrovascular disease or ischemic changes that are causative for cognitive disorders.
Individuals who are continuously taking drugs affecting cognitive functions.
Individuals with unstable disease states that may hamper continuation of the study
Individuals who are participating in other clinical study including CDR, WMS-R, logical memory or MMSE upon enrollment

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takeshi Iwatsubo

Organization

The University of Tokyo Hospital

Division name

Unit for Early and Exploratory Clinical Development

Zip code


Address

7-3-1 hongo Bunkyoku Tokyo

TEL

0358413541

Email

iwatsubo@m.u-tokyo.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kazushi Suzuki

Organization

The University of Tokyo Hospital

Division name

Unit for Early and Exploratory Clinical Development

Zip code


Address

7-3-1 Hongo Bunkyoku Tokyo

TEL

0358415646

Homepage URL


Email

kazusuzuki-tky@umin.ac.jp


Sponsor or person

Institute

The University of Tokyo Hospital
Unit for Early and Exploratory Clinical Development

Institute

Department

Personal name



Funding Source

Organization

Brain/Minds project

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 02 Month 03 Day

Date of IRB

2015 Year 02 Month 19 Day

Anticipated trial start date

2015 Year 07 Month 01 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry

2019 Year 03 Month 31 Day

Date trial data considered complete

2019 Year 03 Month 31 Day

Date analysis concluded

2019 Year 08 Month 31 Day


Other

Other related information



Management information

Registered date

2015 Year 05 Month 11 Day

Last modified on

2019 Year 05 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020292


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name